[CAS NO. 345267-14-3] BCX-1898
PRODUCTS SPECIFICATIONS [345267-14-3]
DESCRIPTION [345267-14-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 340.46 |
| Molecular Formula | C17H32N4O3 |
| SMILES | CCCC(CCC)[C@@H]([C@]1([H])[C@@H](C[C@@H](C1)C(O)=O)NC(N)=N)NC(C)=O |
Summary
BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC 50 s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model [1] [2] .
In Vivo
BCX-1898 (1, 10 mg/kg/day; Oral; 22 days) shows complete protection against the influenza virus with 10 mg/kg/day
[2]
.
BCX-1898 (0.01, 0.1 mg/kg/day; intranasal treatment; 20 days) demonstrates complete protection (10 out of 10 survived)
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus [2] |
| Dosage: | 1, 10 mg/kg/day |
| Administration: | Oral; 22 days |
| Result: | Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] D F Smee, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001 Mar;45(3):743-8.
- [2] Pooran Chand, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem. 2005 Jun 2;13(12):4071-7.